.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,205,082

« Back to Dashboard

Claims for Patent: 9,205,082

Title:Opioid agonist/antagonist combinations
Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
Inventor(s): Kaiko; Robert F. (Weston, CT), Colucci; Robert D. (Newtown, CT)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:14/214,659
Patent Claims: 1. A sustained release oral dosage form, comprising: an orally therapeutically effective dose of an opioid agonist selected from oxycodone and pharmaceutically acceptable salts thereof which is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof, about 2 mg to about 64 mg hydromorphone hydrochloride, about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof, or about 25 mg to about 800 mg tramadol or a pharmaceutically acceptable salt thereof; an opioid antagonist selected from naloxone and pharmaceutically acceptable salts thereof; and a sustained release carrier that contains the opioid agonist and the opioid antagonist; said dosage form having a ratio of opioid antagonist to opioid agonist that provides a combination product which is analgesically effective when the combination product is administered orally, but which (i) is aversive in physically dependent human subjects when abused at a higher dose than said therapeutically effective dose; and (ii) maintains an analgesic effect but does not increase analgesic efficacy of said opioid agonist relative to the same therapeutic dose of opioid agonist when administered to human patients without said opioid antagonist; such that said dosage form is administrable on a twice-a-day or on a once-a-day basis.

2. The oral dosage form of claim 1, wherein the amount of antagonist included in the oral dosage form causes an aversive experience in a physically dependent addict taking about 2-3 times said therapeutically effective dose.

3. The oral dosage form of claim 1, further comprising an additional non-opioid drug selected from an NSAID, a COX-2 inhibitor, acetaminophen, aspirin, an NMDA receptor antagonist, a drug that blocks a major intracellular consequence of NMDA-receptor activation, an antitussive, an expectorant, a decongestant, an antihistamine, and mixtures thereof.

4. The oral dosage form of claim 1, further comprising one or more pharmaceutically acceptable inert excipients.

5. The oral dosage form of claim 1, wherein the naloxone or pharmaceutically acceptable salt thereof is provided in an amount that corresponds to an equiantagonistic amount of naltrexone or a pharmaceutically acceptable salt thereof, and wherein the ratio of the equiantagonistic amount of naltrexone or pharmaceutically acceptable salt thereof to the oxycodone or pharmaceutically acceptable salt thereof is from about 0.037:1 to about 0.296:1.

6. The oral dosage form of claim 5, wherein the ratio of the equiantagonistic amount of naltrexone or pharmaceutically acceptable salt thereof to the oxycodone or pharmaceutically acceptable salt thereof is from about 0.056:1 to about 0.222:1.

7. The oral dosage form of claim 1, wherein the combination product is aversive in physically dependent human subjects when orally abused at a higher dose than said therapeutically effective dose.

8. The oral dosage form of claim 7, wherein the combination product is aversive in physically dependent human subjects when orally abused at about 2-3 times said therapeutically effective dose.

9. The oral dosage form of claim 1, wherein the combination product is aversive in physically dependent human subjects when parenterally abused at a higher dose than said therapeutically effective dose.

10. The oral dosage form of claim 9, wherein the combination product is aversive in physically dependent human subjects when parenterally abused at about 2-3 times said therapeutically effective dose.

11. A method of preventing oral abuse of an oral opioid formulation, comprising: preparing a sustained release oral dosage form which comprises: an orally therapeutically effective dose of an opioid agonist selected from oxycodone and pharmaceutically acceptable salts thereof which is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof, about 2 mg to about 64 mg hydromorphone hydrochloride, about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof, or about 25 mg to about 800mg tramadol or a pharmaceutically acceptable salt thereof; and a sustained release carrier that contains the opioid agonist; and incorporating into the dosage form an opioid antagonist selected from naloxone and pharmaceutically acceptable salts thereof in a ratio to said opioid agonist such that the oral dosage form is analgesically effective when administered orally, but which (i) is aversive in physically dependent human subjects when abused at a higher dose than said therapeutically effective dose; and (ii) maintains an analgesic effect but does not increase analgesic efficacy of said opioid agonist relative to the same therapeutic dose of opioid agonist when administered to human patients without said opioid antagonist; such that said dosage form is administrable on a twice-a-day or on a once-a-day basis.

12. The method of claim 11, wherein the amount of antagonist included in the oral dosage form causes an aversive experience in physically dependent addicts taking about 2-3 times said therapeutically effective dose.

13. The method of claim 11, wherein the naloxone or pharmaceutically acceptable salt thereof is provided in an amount that corresponds to an equiantagonistic amount of naltrexone or a pharmaceutically acceptable salt thereof, and wherein the ratio of the equiantagonistic amount of naltrexone or pharmaceutically acceptable salt thereof to the oxycodone or pharmaceutically acceptable salt thereof is from about 0.037:1 to about 0.296:1.

14. The method of claim 13, wherein the ratio of the equiantagonistic amount of naltrexone or pharmaceutically acceptable salt thereof to the oxycodone or pharmaceutically acceptable salt thereof is from about 0.056:1 to about 0.222:1.

15. A method of treating pain comprising administering the oral dosage form of claim 1 to a patient in need thereof.

16. The method of claim 15, wherein the naloxone or pharmaceutically acceptable salt thereof is provided in an amount that corresponds to an equiantagonistic amount of naltrexone or a pharmaceutically acceptable salt thereof, and wherein the ratio of the equiantagonistic amount of naltrexone or pharmaceutically acceptable salt thereof to the oxycodone or pharmaceutically acceptable salt thereof is from about 0.037:1 to about 0.296:1.

17. The method of claim 16, wherein the ratio of the equiantagonistic amount of naltrexone or pharmaceutically acceptable salt thereof to the oxycodone or pharmaceutically acceptable salt thereof is from about 0.056:1 to about 0.222:1.

18. The method of claim 15, wherein the combination product is aversive in physically dependent human subjects when orally abused at a higher dose than said therapeutically effective dose.

19. The method claim 18, wherein the combination product is aversive in physically dependent human subjects when orally abused at about 2-3 times said therapeutically effective dose.

20. The method claim 15, wherein the combination product is aversive in physically dependent human subjects when parenterally abused at a higher dose than said therapeutically effective dose.

21. The method claim 20, wherein the combination product is aversive in physically dependent human subjects when parenterally abused at about 2-3 times said therapeutically effective dose.

22. The oral dosage form of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof.

23. The oral dosage form of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2 mg to about 64 mg hydromorphone hydrochloride.

24. The oral dosage form of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof.

25. The oral dosage form of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 25 mg to about 800 mg tramadol or a pharmaceutically acceptable salt thereof.

26. The method of claim 15, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof.

27. The method of claim 15, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2 mg to about 64 mg hydromorphone hydrochloride.

28. The method of claim 15, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof.

29. The method of claim 15, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 25 mg to about 800 mg tramadol or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc